Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Rating of “Buy” from Brokerages

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) have received an average recommendation of “Buy” from the six ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy recommendation. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $30.50.

CPRX has been the subject of several recent research reports. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a report on Monday, November 11th. HC Wainwright reiterated a “buy” rating and issued a $30.00 target price on shares of Catalyst Pharmaceuticals in a research note on Friday, November 8th. StockNews.com upgraded Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Finally, Citigroup upped their price target on Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, August 9th.

Catalyst Pharmaceuticals Stock Down 5.0 %

Catalyst Pharmaceuticals stock opened at $20.60 on Tuesday. The firm has a fifty day moving average of $20.99 and a 200-day moving average of $18.34. Catalyst Pharmaceuticals has a 52-week low of $13.00 and a 52-week high of $24.27. The firm has a market capitalization of $2.46 billion, a P/E ratio of 17.46, a PEG ratio of 3.51 and a beta of 0.75.

Insider Buying and Selling

In other news, insider Steve Miller sold 150,000 shares of the stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the transaction, the insider now owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This trade represents a 18.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction dated Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the completion of the sale, the director now directly owns 348,874 shares of the company’s stock, valued at approximately $7,012,367.40. This represents a 4.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 11.00% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its holdings in shares of Catalyst Pharmaceuticals by 62.1% during the third quarter. GAMMA Investing LLC now owns 1,778 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 681 shares during the period. nVerses Capital LLC acquired a new stake in Catalyst Pharmaceuticals during the third quarter worth about $50,000. Larson Financial Group LLC lifted its holdings in Catalyst Pharmaceuticals by 27,218.2% in the third quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 2,994 shares during the last quarter. CWM LLC boosted its stake in Catalyst Pharmaceuticals by 686.5% in the second quarter. CWM LLC now owns 4,066 shares of the biopharmaceutical company’s stock valued at $63,000 after acquiring an additional 3,549 shares during the period. Finally, Meeder Asset Management Inc. bought a new position in shares of Catalyst Pharmaceuticals during the second quarter valued at approximately $70,000. Institutional investors own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.